ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1710

CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus

Mitra Maz1, Hong Shi2, Sonya Wolf-Fortune3, Shannon Estadt3, Alayka Reddy3, Rachael Wasikowski3, Alex Tsoi3, Celine Berthier3 and J. Michelle Kahlenberg3, 1University of Michigan Medical School, Ann Arbor, MI, 2Department of Internal Medicine/Division of Rheumatology, Vascular Biology Center, Augusta, GA, 3University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2022

Keywords: Cutaneous, Dendritic cells, Monocytes/macrophages, Mouse Models, Lupus, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Animal Models Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by overproduction of type I interferons (IFNs) and sensitivity to ultraviolet (UV) light. Though UV is a known trigger of SLE and SLE-associated skin lesions, mechanisms of UV-induced flare remain elusive. Previous work from our lab suggests the importance of myeloid cells in cutaneous inflammatory responses in SLE. However, mechanisms of recruitment, differentiation, and function of these cells are unknown and represent the goal of this study.

Methods:
Mice: 8-12 week old female wild-type Balb/c, lupus-prone New Zealand Mixed (NZM) 2328, and lupus-prone iNZM (NZM2328 background with type I IFN receptor alpha chain knockout) mice were used per our University of Michigan IACUC-approved protocol.

UV irradiation: Dorsal fur was removed with Veet cream. Mice were placed in a restrainer with facial protection and treated with 100mJ/cm2 UVB daily for 5 days (=chronic exposure) or a single dose of 300mJ/cm2 UVB (=acute exposure) using the UV-2 ultraviolet irradiation system (Tyler Research) at a wavelength of 310 nm.

Flow Cytometry: UV-exposed full-thickness dorsal skin was harvested, mechanically dissociated, and incubated with digestion enzymes (0.1g/ml deoxyribonuclease type I, 0.1g/ml hyaluronidase type V, 0.5g/ml collagenase) for 30 minutes at 37ºC. Cells were stained for: viability, CD11b, CD11c, Ly6C, MHC-II, Ly6G, CD3. Data was collected on a Cytek Aurora flow cytometer and analyzed using FlowJo flow cytometry analysis software.

Results: RNA sequencing of UV-exposed skin of NZM, iNZM, and Balb/c mice demonstrated upregulation of monocyte chemoattractants, including CCL2, in NZM >iNZM and Balb/c. Using cell type enrichment analysis through xCell webtool, we further identified enrichment of myeloid populations in UV-exposed NZM skin >iNZM and Balb/c, suggesting that type I IFNs are driving myeloid gene signatures in lupus-prone skin. We verified myeloid enrichment by flow cytometry, wherein we identified type I IFN-enhanced monocyte recruitment in NZM skin vs. Balb/c following acute UV exposure. Exposing mice to chronic UV dosing led to increased monocyte-derived dendritic cells (moDCs) in irradiated NZM skin. Furthermore, we identified increased MHC class II expression in skin-recruited moDCs of chronically UV-exposed NZM compared to iNZM and Balb/c, suggesting type I IFNs are aberrantly activating antigen presenting cells after UV exposure. Blockade of CCL2 with neutralizing antibodies blocked the interferon-enhanced recruitment of monocytes to UV-irradiated NZM skin, with little effect on iNZM and Balb/c monocyte recruitment. Applying the same CCL2 blockade to chronically UV exposed mice resulted in diminished moDC numbers in UV-exposed NZM, but not iNZM or Balb/c, skin. Sources of CCL2 production in human SLE skin were examined and SLE compared to healthy control keratinocytes produce CCL2 following UVB exposure.

Conclusion: We have identified that CCL2 drives the observed type I IFN-enhanced increase in monocyte and moDC numbers in UV-irradiated lupus-prone skin. Further studies will elucidate mechanisms of differentiation and function of IFN-educated moDCs in UV-driven immune activation in SLE.


Disclosures: M. Maz, None; H. Shi, None; S. Wolf-Fortune, None; S. Estadt, None; A. Reddy, None; R. Wasikowski, None; A. Tsoi, None; C. Berthier, None; J. Kahlenberg, Q32 Bio, Celgene/Bristol Myers Squibb, Ventus Therapeutics, Rome Therapeutics, Janssen, AstraZeneca, Eli Lilly, GlaxoSmithKline, Bristol Myers Squibb, Avion Pharmaceuticals, Provention Bio, Aurinia Pharmaceuticals, Boehringer Ingelheim.

To cite this abstract in AMA style:

Maz M, Shi H, Wolf-Fortune S, Estadt S, Reddy A, Wasikowski R, Tsoi A, Berthier C, Kahlenberg J. CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/ccl2-drives-interferon-enhanced-monocytosis-in-uv-mediated-skin-injury-in-murine-lupus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ccl2-drives-interferon-enhanced-monocytosis-in-uv-mediated-skin-injury-in-murine-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology